Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 4th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 4th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

October 5th 2015

Weight-Loss Surgery Can Prevent Cancer, Now Let's Pay for It

Surabhi Dangi-Garimella, PhD

The evidence of weight-loss improving overall well-being and predisposition to chronic as well as acute conditions is mounting. We now need coverage policies that can help patients take advantage of weight loss procedures.

October 5th 2015

Dr Mark Kris Explains Changes Emerging From Genetic Testing

The use of genetic testing has led to a radical change within certain specialties and hospital departments. And although doctors are being asked to do more, they do it gladly because the work leads to better treatment decisions for patients, said Mark G. Kris, MD, William and Joy Ruane chair in thoracic oncology at Memorial Sloan Kettering Cancer Center.

October 5th 2015

Who Pays for Immuno-Oncology?

Surabhi Dangi-Garimella, PhD

Reimbursement remains a primary concern with the new immuno-oncology agents. Who pays and how do you ensure payment was fervently discussed by oncologists at the recent ICLIO meeting hosted by the Association of Community Cancer Centers.

October 2nd 2015

Access to Palliative Care Remains an Issue in US Hospitals

Surabhi Dangi-Garimella, PhD

A study reports that despite the steady growth in hospital-based palliative care programs, access is sketchy and is driven by geographic location and hospital ownership.

October 1st 2015

Cancer Survivor Clinics Can Reduce ED Utilization, Study Shows

Surabhi Dangi-Garimella, PhD

A government-funded network of specialized survivor clinics in Ontario, Canada, significantly decreased emergency department visits among adult survivors of childhood cancer.

October 1st 2015

WISDOM Study Aims to Personalize Breast Cancer Screening

AJMC Staff

The study plans to evaluate the impact of a personalized approach to breast cancer screening over an annual mammogram.

October 1st 2015

Opdivo-Yervoy Combination Approved for Metastatic Melanoma Harboring Wild-Type BRAF

Surabhi Dangi-Garimella, PhD

This approval marks the first-ever for 2 immuno-oncology agents in cancer treatment.

September 30th 2015

A Breast Cancer Risk Assessment Tool That Includes Breast Density Measures

Surabhi Dangi-Garimella, PhD

The result of a multicollaborative effort, the study published in the Journal of Clinical Oncology found that incorporating breast density information in the risk calculator could accurately estimate women's risk for the disease.

September 30th 2015

Reply to "Transforming Oncology Care": Advancing Value, Accessing Innovation

Rebecca Paradis, MPA

Patient access to innovation may be at risk as new payment models emerge in oncology.

September 30th 2015

Public Strongly Favors Medicare Funding for End-of-Life Talks, Poll Finds

Mary K. Caffrey

The findings come as CMS is poised to finalize a rule to pay doctors to counsel patients about end-of-life treatment options.

September 30th 2015

Conflict of Interest Rampant in Academic-Industry Partnerships

Surabhi Dangi-Garimella, PhD

A study published in BMJ measured the prevalence, annual compensation, and beneficial stock ownership of directors from publicly traded healthcare companies who had academic affiliations.

September 29th 2015

ECC Data Recommends Fewer but Stronger Doses of Radiation for Prostate Tumors

AJMC Staff

The CHHiP trial found fewer high-dose radiotherapy was as effective as more number of low-dose radiotherapy in men with prostate cancer.

September 29th 2015

CAD Increases Cost and May Even Miss Detecting Breast Cancers, Says BCSC Study

Surabhi Dangi-Garimella, PhD

An NCI-funded Breast Cancer Surveillance Consortium study has found that computer-aided detection and interpretation of mammograms does not add any value to breast cancer screening.

September 29th 2015

The Patient Will See You Now: Part 1

Debra Madden

My visit to the gynecologist's office following treatment for breast cancer and a subsequent reconstructive surgery was a rude awakening.

September 28th 2015

Results of Gene Panel Test Can Determine Need for Chemotherapy in Breast Cancer

Surabhi Dangi-Garimella, PhD

A prospective study that enrolled more than 10,000 women with hormone-receptor—positive, HER2-negative breast cancer has found that their response to a 21-gene test can identify patients who can avoid chemotherapy.

September 28th 2015

Dr Amy Davidoff Highlights the Benefits of Palliative Care, Discusses Biosimilars

Palliative care should enter into the discussion with patients with cancer as early as possible as it can manage symptoms from therapy or it can provide comfort to patients who cannot afford or choose to forgo therapy, said Amy Davidoff, PhD, MS. Plus, she discusses the impact biosimilars may have on therapy costs.

September 28th 2015

Distinct Molecular Tumor Profile in Younger CRC Patients Recognized

Surabhi Dangi-Garimella, PhD

Data presented at the ongoing European Cancer Congress has identified a different epigenetic profile in the tumors of younger colorectal cancer patients, information that can help improve treatment options in this population.

September 27th 2015

Dr Ira Klein Discusses the Use of Fee-for-Service in Oncology

Although CMS has introduced a strict timeline to move to value-based payments, its new Oncology Care Model is partially relying on fee-for-service, and that's a good thing in the case of oncology, said Ira Klein, MD, MBA, senior director of quality, Strategic Customer Group at The Janssen Pharmaceutical Companies of Johnson & Johnson.

September 26th 2015

This Week in Managed Care: September 26, 2015

Top managed care stories this week include the follow up to the National Academy of Medicine's groundbreaking "To Err Is Human" report, findings on the sharp increase in deductibles, and discussing costs in cancer care.

September 25th 2015

First-Ever Therapeutic HPV Vaccine Promising Against Cervical Cancer

Surabhi Dangi-Garimella, PhD

Developed by Inovio Pharmaceuticals, the vaccine has shown the potential to impact precancerous cervical lesions.

September 25th 2015

Results at ESMO Focus on Companion Diagnostics, Avoiding Overtreatment in Prostate Cancer

AJMC Staff

Posters focus on next-generation sequencing ovarian cancer and identify candidates for treatment with PARP inhibitors.

September 25th 2015

Molecularly Targeted SHIVA Trial Fails to Improve Outcomes in Refractory Cancer Patients

Surabhi Dangi-Garimella, PhD

The trial, conducted in France, was a proof-of-concept study to evaluate the efficacy of targeted agents in patients, based on their tumor's molecular profile.

September 25th 2015

The Dawning of Democratized Cancer Care

Emmanuel F. Petricoin III, PhD

Innovative trials offer the promise that patients can be treated in their own communities instead of traveling to faraway cancer centers.

September 24th 2015

Startup's Direct-to-Consumer Genetic Test Receives FDA Attention

Surabhi Dangi-Garimella, PhD

In a letter to Pathway Genomics, the FDA has expressed interest in discussing the company's validation strategy as well as evaluating data on clinical sensitivity and specificity of the CancerIntercept Detect test.

September 24th 2015

ASCO President Julie Vose, MD, to Give Keynote at AJMC's Patient-Centered Oncology Care Meeting

The fourth annual meeting of Patient-Centered Oncology Care, set for November 19-20, 2015, in Baltimore, Maryland, will feature a premiere multi-stakeholder lineup where leading payers, providers, and leaders from pharma will discuss how to deliver value-based care as cost of breakthrough therapies continues to climb. Julie Vose, MD, MBA, FASCO, the president of the American Society of Clinical Oncology, will give the keynote address.

September 24th 2015

USPSTF Recommendation May Increase Risk for Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in The Journal of Urology suggests the Grade D recommendation for PSA-based screening may place those with intermediate and high-risk prostate cancer at risk.

September 23rd 2015

Dr Julie Vose on the Importance of Attending PCOC15

Julie Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology and keynote speaker at Patient-Centered Oncology Care 2015, explains the importance of the meeting and how patients benefit when a diverse set of stakeholders come together in one room.

September 23rd 2015

Dissecting the Patient Perception of FDA's Breakthrough Designation

Surabhi Dangi-Garimella, PhD

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

September 23rd 2015

Clinton Seeks Cap on Drug Expenses, Would Let Medicare Negotiate

Mary K. Caffrey

Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.

September 23rd 2015

Physicians Believe in Biosimilars but Lack Awareness, Says Report by Quantia

Surabhi Dangi-Garimella, PhD

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

...

121 122 123 124 125 126 127 128 129

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions